Daniel Allen Gold net worth and biography

Daniel Gold Biography and Net Worth

Director of Roivant Sciences

Daniel Gold has served as Director of Roivant since 2020. Mr. Gold serves as the CEO, managing partner and founder of QVT Financial LP, an asset management company with offices in New York and New Delhi. QVT Financial, through its managed and affiliated multi-strategy funds, is an experienced global investor in multiple industries, including biotech, financial, shipping and offshore industries. Mr. Gold founded QVT Financial LP in 2003. Mr. Gold holds an A.B. in Physics from Harvard College. Mr. Gold also currently serves on the board of public companies MP Materials, Okeanis Eco Tankers Corp. and Awilco Drilling PLC, in addition to various private companies.

What is Daniel Allen Gold's net worth?: The estimated net worth of Daniel Allen Gold is at least $437.59 million as of February 13th, 2026. Gold owns 15,127,329 shares of Roivant Sciences stock worth more than $437,588,246 as of February 27th. This net worth estimate does not reflect any other investments that Gold may own. Learn More about Daniel Allen Gold's net worth.
How do I contact Daniel Allen Gold?: The corporate mailing address for Gold and other Roivant Sciences executives is Clarendon House, 2 Church Street, Hamilton Parish HM 11. Roivant Sciences can also be reached via phone at 44-20-7400-3347 and via email at [email protected]. Learn More on Daniel Allen Gold's contact information.
Has Daniel Allen Gold been buying or selling shares of Roivant Sciences?: During the last quarter, Daniel Allen Gold has sold $21,293,026.00 of Roivant Sciences stock. Most recently, Daniel Allen Gold sold 375,784 shares of the business's stock in a transaction on Friday, February 13th. The shares were sold at an average price of $26.50, for a transaction totalling $9,958,276.00. Following the completion of the sale, the director now directly owns 15,127,329 shares of the company's stock, valued at $400,874,218.50. Learn More on Daniel Allen Gold's trading history.
Who are Roivant Sciences' active insiders?: Roivant Sciences' insider roster includes Matthew Gline (CEO), Daniel Gold (Director), Rakhi Kumar (CAO), Keith Manchester (Director), Richard Pulik (CFO), Vivek Ramaswamy (Major Shareholder), Mayukh Sukhatme (President and Chief Investment Officer), Frank Torti (Insider), and Eric Venker (COO). Learn More on Roivant Sciences' active insiders.
Are insiders buying or selling shares of Roivant Sciences?: In the last year, Roivant Sciences insiders bought shares 2 times. They purchased a total of 16,669,981 shares worth more than $350,049,943.05. In the last year, insiders at the sold shares 54 times. They sold a total of 26,216,037 shares worth more than $508,898,353.56. The most recent insider tranaction occured on February, 23rd when insider Frank Torti sold 587,390 shares worth more than $16,159,098.90. Insiders at Roivant Sciences own 10.8% of the company. Learn More about insider trades at Roivant Sciences.
Information on this page was last updated on 2/23/2026.

Daniel Allen Gold Insider Trading History at Roivant Sciences

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/13/2026	Sell	375,784	$26.50	$9,958,276.00	15,127,329
2/11/2026	Sell	425,000	$26.67	$11,334,750.00	15,928,113
12/17/2025	Sell	777,332	$23.07	$17,933,049.24	16,353,113
12/16/2025	Sell	917,282	$23.04	$21,134,177.28	17,130,445
11/19/2025	Sell	1,300,000	$20.23	$26,299,000.00	18,047,727

Daniel Allen Gold Buying and Selling Activity at Roivant Sciences

Roivant Sciences Company Overview

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

Today's Range

Now: $28.93

$28.30

$28.93

50 Day Range

MA: $23.80

$21.14

$28.66

2 Week Range

Now: $28.93

$8.73

$29.20

Volume

2,494,150 shs

Average Volume

6,439,963 shs

Market Capitalization

$20.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.22